{"id":407739,"date":"2025-10-12T00:15:00","date_gmt":"2025-10-11T22:15:00","guid":{"rendered":"https:\/\/medizinonline.com\/nuevos-horizontes-de-los-inhibidores-de-btk-a-la-remielinizacion\/"},"modified":"2025-10-11T23:38:30","modified_gmt":"2025-10-11T21:38:30","slug":"nuevos-horizontes-de-los-inhibidores-de-btk-a-la-remielinizacion","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/nuevos-horizontes-de-los-inhibidores-de-btk-a-la-remielinizacion\/","title":{"rendered":"Nuevos horizontes: de los inhibidores de BTK a la remielinizaci\u00f3n"},"content":{"rendered":"\n<p><strong>Las formas progresivas de la esclerosis m\u00faltiple -la EM primaria progresiva (EMPP) y la EM secundaria progresiva (EMSP)- han planteado retos particulares a los neur\u00f3logos durante d\u00e9cadas. A diferencia de la EM recurrente-remitente (EMRR), en la que el control de la inflamaci\u00f3n mediante terapias modificadoras de la enfermedad es ahora el est\u00e1ndar cl\u00ednico, los avances terap\u00e9uticos en el espectro progresivo siguen siendo fragmentarios. En los \u00faltimos a\u00f1os, sin embargo, han surgido nuevos enfoques: desde inmunomoduladores dirigidos hasta inhibidores de la tirosina quinasa de Bruton y estrategias de remielinizaci\u00f3n, pasando por innovadores procesos celulares y g\u00e9nicos.  <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fnuevos-horizontes-de-los-inhibidores-de-btk-a-la-remielinizacion%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Las formas progresivas de la esclerosis m\u00faltiple -la EM primaria progresiva (EMPP) y la EM secundaria progresiva (EMSP)- han planteado retos particulares a los neur\u00f3logos durante d\u00e9cadas. A diferencia de&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Fnuevos-horizontes-de-los-inhibidores-de-btk-a-la-remielinizacion%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":407741,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Esclerosis m\u00faltiple progresiva  ","footnotes":""},"category":[11475,11478,11364,11328,11552],"tags":[84991,12343,84993,74184,84992],"powerkit_post_featured":[],"class_list":["post-407739","post","type-post","status-publish","format-standard","has-post-thumbnail","category-estudios","category-formacion-continua","category-genetica","category-neurologia","category-rx-es","tag-em-progresiva","tag-esclerosis-multiple","tag-fenebrutinib-es","tag-remielinizacion","tag-tolebrutinib-es","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-29 09:02:08","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/407739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=407739"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/407739\/revisions"}],"predecessor-version":[{"id":407743,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/407739\/revisions\/407743"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/407741"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=407739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=407739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=407739"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=407739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}